MAP2K7 and cancer: Sorafenib 39 (Figure 9) is a potent multi-target kinase inhibitor, that suppressed cancer cells proliferation by inhibiting the activity of RAF-1, B-RAF and RAS/RAF/MEK/ERK signaling pathways [187].